Oxigene (OXGN -23%) sinks to a new 52-week low after halting Phase 2 and 3 studies of its...

|By:, SA News Editor

Oxigene (OXGN -23%) sinks to a new 52-week low after halting Phase 2 and 3 studies of its thyroid cancer drug candidate Zybrestat due to lack of funding, and announces a restructuring whereby it will reduce its workforce by 60%.